A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS

ग्रंथसूची विवरण
मुख्य लेखकों:	Vale, C, Tierney, J, Meade, A, Fisher, D, Kaplan, R, Adams, R, Maughan, T, Parmar, M
स्वरूप:	Journal article
प्रकाशित:	2009

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
द्वारा: Vale, C, और अन्य
प्रकाशित: (2009)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
द्वारा: Maughan, T, और अन्य
प्रकाशित: (2010)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
द्वारा: Maughan, T, और अन्य
प्रकाशित: (2009)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
द्वारा: Vale, C, और अन्य
प्रकाशित: (2012)

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
द्वारा: Vale, C, और अन्य
प्रकाशित: (2012)

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
द्वारा: Adams, R, और अन्य
प्रकाशित: (2009)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
द्वारा: Wasan, H, और अन्य
प्रकाशित: (2011)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
द्वारा: Smith, C, और अन्य
प्रकाशित: (2010)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
द्वारा: Adams, R, और अन्य
प्रकाशित: (2016)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
द्वारा: Beth O. Van Emburgh, और अन्य
प्रकाशित: (2016-12-01)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
द्वारा: Adams, R, और अन्य
प्रकाशित: (2009)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
द्वारा: Yohanes Ramli.
प्रकाशित: (2008)

Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database
द्वारा: Shuhei Suzuki, और अन्य
प्रकाशित: (2024-12-01)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
द्वारा: Wood, G, और अन्य
प्रकाशित: (2017)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
द्वारा: Maughan, T, और अन्य
प्रकाशित: (2010)

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
द्वारा: Xiaona Lu, और अन्य
प्रकाशित: (2023-11-01)

CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
द्वारा: Thiago David Alves PINTO, और अन्य
प्रकाशित: (2021-06-01)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
द्वारा: Susan D. Richman, और अन्य
प्रकाशित: (2011-01-01)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
द्वारा: Chen DT, और अन्य
प्रकाशित: (2019-02-01)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
द्वारा: Reilly, R, और अन्य
प्रकाशित: (2002)

HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG)
द्वारा: Lockwood, C, और अन्य
प्रकाशित: (1995)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
द्वारा: Adams, R, और अन्य
प्रकाशित: (2017)

EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
द्वारा: Mauro Moroni, और अन्य
प्रकाशित: (2011-12-01)

IMGT/mAb-KG: the knowledge graph for therapeutic monoclonal antibodies
द्वारा: Gaoussou Sanou, और अन्य
प्रकाशित: (2024-06-01)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
द्वारा: Madi, A, और अन्य
प्रकाशित: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
द्वारा: Madi, A, और अन्य
प्रकाशित: (2012)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
द्वारा: Adams, R, और अन्य
प्रकाशित: (2010)

Multispecificity of a recombinant anti-ras monoclonal antibody
द्वारा: Schrader, John W., और अन्य
प्रकाशित: (2017)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
द्वारा: Maughan, T, और अन्य
प्रकाशित: (2010)

Essay 4. What kinds of efficacies evade randomised controlled trials (RCTs)?
द्वारा: Alford, M
प्रकाशित: (2017)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
द्वारा: Samantha I. Liang, और अन्य
प्रकाशित: (2018-03-01)

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB
द्वारा: Taciana Manso, और अन्य
प्रकाशित: (2023-05-01)

Radiolabeling and biodistribution of monoclonal antibody (MAb) anti-CD20 with iodine-131
द्वारा: Akinkunmi Ganiyu Akanji, और अन्य
प्रकाशित: (2005-10-01)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
द्वारा: Adams, R, और अन्य
प्रकाशित: (2008)

A NOVEL COLORECTAL CANCER SUSCEPTIBILITY SNP IN THE EIF3H PROMOTER INFLUENCES PATIENT SURVIVAL AND RESPONSE TO TREATMENT
द्वारा: Cheadle, J, और अन्य
प्रकाशित: (2010)

Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework
द्वारा: Wilson, C, और अन्य
प्रकाशित: (2018)

Epitope mapping of an anti-diacylglycerol kinase delta monoclonal antibody DdMab-1
द्वारा: Masato Sano, और अन्य
प्रकाशित: (2020-12-01)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
द्वारा: Adams, R, और अन्य
प्रकाशित: (2011)

The use of healthcare systems data for RCTs
द्वारा: Alice-Maria Toader, और अन्य
प्रकाशित: (2024-01-01)

<it>EGFR</it> gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
द्वारा: Yang Zu-Yao, और अन्य
प्रकाशित: (2012-08-01)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS

समान संसाधन

समान संसाधन